Predicting erectile function outcome in men after radical prostatectomy for prostate cancer

BJU Int. 2012 Aug;110(3):422-6. doi: 10.1111/j.1464-410X.2011.10757.x. Epub 2011 Dec 19.

Abstract

Objective: • To identify the reported rates of potency after prostatectomy in the recent literature for men without preoperative erectile dysfunction (ED) and to develop a statistical model for predicting the expected potency after prostatectomy.

Materials and methods: • A Medline search was conducted with the keywords 'potency' and 'prostatectomy' from 2003 to 2009. • In total, 33 studies in the English language reporting pre- and postoperative erectile function were identified. • Data from studies reporting outcome after open, laparoscopic and robot-assisted prostatectomy were analyzed separately. • Only data obtained from potent men before surgery were included in the analysis.

Results: • In potent men before surgery, the main predictors of post-treatment erectile function are age and time after treatment. • The cumulative range of potency rates at 48 months for all ages (45-75 years) was 49-74% for open, 58-74% for laparoscopic and 60-100% for robotic prostatectomy. • The predicted outcome differs by type of operation and patient age.

Conclusions: • Men aged <60 years have a significant likelihood of regaining erectile function after radical prostatectomy. • The reported statistical model provides a reliable estimation of erectile function outcome after prostatectomy for men with localized prostate cancer and intact erectile function.

Publication types

  • Review

MeSH terms

  • Aged
  • Erectile Dysfunction / drug therapy
  • Erectile Dysfunction / etiology*
  • Erectile Dysfunction / physiopathology
  • Humans
  • Laparoscopy / adverse effects
  • Laparoscopy / methods
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Postoperative Period
  • Preoperative Period
  • Prostatectomy / adverse effects*
  • Prostatectomy / methods
  • Prostatic Neoplasms / physiopathology
  • Prostatic Neoplasms / surgery*
  • Recovery of Function
  • Regression Analysis
  • Robotics / methods
  • Treatment Outcome

Substances

  • Phosphodiesterase 5 Inhibitors